Cullinan Oncology, Inc.
NASDAQ:CGEM
11.6 (USD) • At close December 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Cullinan Oncology, Inc. |
Symbool | CGEM |
Munteenheid | USD |
Prijs | 11.6 |
Beurswaarde | 675,440,160 |
Dividendpercentage | 0% |
52-weken bereik | 9.24 - 30.189 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Nadim Ahmed |
Website | https://www.cullinanoncology.com |
An error occurred while fetching data.
Over Cullinan Oncology, Inc.
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)